Navigation Links
Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
Date:9/27/2007

ernational biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options.

For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based ... today announced its financial results for the three months ... $861,509 for the three months ended March 31, 2009, ... Net losses were partially offset by grant revenues ...
... PARMA, Italy, May 7 The Parma Group has ... is laying the groundwork to,acquire control of the American ... associated company in the world,s largest,pharmaceuticals market. This presence ... and new projects in the area of respiratory illnesses. ...
... a private company developing the Apollo next-generation fluidics ... F. Marion has accepted a board position to ... was former CEO of Applied Biosystems and today ... backed companies."Andre Marion brings an immense depth of ...
Cached Biology Technology:GeoVax Labs, Inc. Announces First Quarter Financial Results 2GeoVax Labs, Inc. Announces First Quarter Financial Results 3GeoVax Labs, Inc. Announces First Quarter Financial Results 4GeoVax Labs, Inc. Announces First Quarter Financial Results 5The Chiesi Group Lands in the United States 2The Chiesi Group Lands in the United States 3Andre Marion Joins Microchip Biotechnologies' Board of Directors 2
(Date:4/15/2014)... new study from the Women,s Health Initiative (WHI) shows ... symptoms. The study was published online today in ... Society., The authors analyzed the relationship between the blood ... symptoms, including hot flashes, night sweats, sleep disturbance, concentration, ... calcium and vitamin D WHI trial. , There was ...
(Date:4/15/2014)... 2020 how high sea levels will rise into the ... Florida International University scientist Rene Price. , Price is ... Coastal Everglades Long-Term Ecological Research (LTER) site, one of ... reefs to deserts, mountains to salt marshes around the ... one of the most certain consequences of climate change. ...
(Date:4/15/2014)... If an insect drew a line as it ... a tangled mess. But there,s method to that mess, ... engineering and physics, who tries to find simple physical ... https://cornell.box.com/tbeetle , It turns out the tiger beetle, ... reorientation dance as it chases its prey at blinding ...
Breaking Biology News(10 mins):Low Vitamin D may not be a culprit in menopause symptoms 2Long-term predictions for Miami sea level rise could be available relatively soon 2Photo: Tiger beetle's chase highlights mechanical law 2
... , SUNNYVALE, Calif. and ... the technology leader in intelligent video, announced that a major UK ... lane security system using Vidient,s SmartCatch video analytics suite, while a ... another such system.   , The SmartCatch system is a major ...
... COLD SPRING HARBOR, N.Y. (Mon., Feb. 1, ... long been the standard method for identifying genetic regulatory ... control regions. Sequences that are nucleosome-depleted, presumably to provide ... I. Traditional low-throughput methods use Southern blots to ...
... The search for new drug compounds is probably worse ... scientists are limited in the size of the haystacks ... impossible to screen or search through super-large libraries of ... is enormous interest in identifying synthetic molecules that bind ...
Cached Biology News:Vidient SmartCatch Protecting Exit Lanes at Major UK Airport 2Vidient SmartCatch Protecting Exit Lanes at Major UK Airport 3High-throughput analysis of gene regulation, DNA synthesis in Cold Spring Harbor Protocols 2Scripps Research scientists create new way to screen libraries of 10 million or more compounds 2Scripps Research scientists create new way to screen libraries of 10 million or more compounds 3
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
... Mouse monoclonal [SPM278] to 67kD Laminin ... lung carcinoma N592 live cells (Human). ... Not yet tested in other species. ... major glycoproteins of basement membrane, displays multiple ...
Hybridization Buffer 3.6 ml...
...
Biology Products: